Local 12: UC gives TAP students new outlook on life
October 18, 2019
Article has no nextliveshere tags assigned
Article has no topics tags assigned
Article has no colleges tags assigned
Description is empty
Article has no audiences tags assigned
Article has no units tags assigned
Contacts are empty
These messages will display in edit mode only.
CINCINNATI—“Let’s Talk About Sex.”
That catchy playful hip-hop tune from artists Salt-N-Pepa tackled a serious subject and ruled 90s radio for a decade. That earworm also stays on the mind of one University of Cincinnati (UC) College of Medicine researcher who is trying to find a better treatment for pneumocystis pneumonia.
It turns out the yeast-like fungus and human pathogen needs sex to thrive.
When the pathogen revs up it attacks the lungs, multiplies and can be transmitted to other hosts through a cough. Pneumocystis pneumonia plays havoc on the fragile immune systems of patients living with HIV, individuals undergoing cancer treatment or those receiving an organ transplant, says Melanie Cushion, PhD, senior associate dean for research in the UC College of Medicine.
Cushion has snagged a $1.9 million four-year grant from the National Heart, Lung and Blood Institute (1R01HL146266-01) to figure out how to stop the fungi that cause pneumocystis pneumonia from reproducing. She will be testing whether anti-fungal agents known as echinocandins could be used as part of a therapy to block the formation of asci, a life cycle stage that results from sexual replication and is needed for transmission of the pathogen to a new host.
Her research aligns with UC President Neville Pinto’s innovation agenda, one of the platforms of the university’s strategic direction, Next Lives Here.
“We have found in mouse models that without the formation of asci, the infection cannot be transmitted to uninfected mice,” says Cushion, also a professor in the UC Division of Infectious Diseases. “It provides strong evidence that these asci are the agents of the infection—a concept suspected, but heretofore not proven. Our analysis has shown that these echinocandin-treated fungi were trying to proceed with sexual replication but could not due to a lack of beta-glucan, an integral cell wall component in asci.”
Cushion says the echinocandins don’t attack non-beta glucan producing life cycles in pneumocystis pneumonia, which can remain in the lungs despite treatment of up to three weeks. Researchers hope their knowledge will help us understand how long-term use of echinocandins may affect the bodies of immune-compromised patients and if it will eventually rid their systems of pneumocystis pneumonia.
“In a clinic setting, the echinocandin should not be given as a monotherapy as cessation of therapy allows the asci to return,” says Cushion. “Patients are going to need something else to kill the trophic life forms that linger behind in the lungs. Three weeks of treatment with echinocandins is the standard regimen, but what if we take it out to three months? Will it go away?”
“If the fungi that remain after extended treatment with an echinocandin disappear, this would provide the evidence that sexual replication is obligatory for pneumocystis,” says Cushion.
Cushion is working with co-investigator Alexey Porollo, PhD, associate professor in the UC Department of Pediatrics and researcher at Cincinnati Children’s.
“Pneumocystis species live a parasitic life style and are not cultivable outside their mammalian hosts,” says Porollo. “This severely limits studies of these fungi at molecular level and hinders the design of new drugs against this pathogen.”
“A vast majority of genes of this fungus are not functionally annotated, which also presents a huge challenge to investigate this organism using standard omics tools,” says Porollo. “However, it makes it more interesting to study such an organism, as many areas of its biology still lie in an uncharted territory. In addition to probing the extended therapy with echinocandins, our collaborative efforts tackle such riddles in pneumocystis biology as metabolic strategies, tolerance to excessive cytotoxic labile copper environment, and host specificity.”
Featured photo of Dr. Cushion by Colleen Kelley/UC Creative Services and headshot of Dr. Porollo courtesy of Cincinnati Children's.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
October 18, 2019
October 18, 2019
Many people search the internet for information about a medical condition they are experiencing. Dr. Carl Fichtenbaum of the Division of Infectious Diseases at the UC College of Medicine talked to 700 WLW radio about the potential pitfalls of that practice.
October 16, 2019